Hikma Pharmaceuticals (STU:H5P) Beta: 0.5217 (As of Jun. 27, 2026)


STU:H5P Hikma Pharmaceuticals PLC STU:H5P
84 GF Score
Price €17.74
GF Value €24.42
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Beta?

Hikma Pharmaceuticals STU:H5P 84 Beta is 0.5217 as of Jun. 27, 2026. GuruFocus rates STU:H5P with a GF Score™ of 84/100 and a GF Value™ of €24.42 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Hikma Pharmaceuticals's Beta is 0.5217.


Hikma Pharmaceuticals  (STU:H5P) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Hikma Pharmaceuticals Beta Related Terms


Hikma Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Beta Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.90 0.15 -0.44

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.86 0.15 0.83 -0.44

STU:H5P vs ZTS, UTHR, VTRS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's Beta falls into.


STU:H5P
84GF Score
Hikma Pharmaceuticals PLC STU:H5P
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5217 mean?
Hikma Pharmaceuticals (STU:H5P) has a Beta of 0.5217 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Beta too high?
Hikma Pharmaceuticals' current Beta is 0.5217. Overall, Hikma Pharmaceuticals has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Beta compare to ZTS and UTHR?
Hikma Pharmaceuticals' Beta of 0.5217 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Beta is 0.5217. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (STU:H5P) is currently considered Modestly Undervalued. The stock's GF Value™ is €24.42, compared to a current price of €17.74 — trading 27.4% below its estimated fair value. The current Beta is 0.5217. Hikma Pharmaceuticals' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Hikma Pharmaceuticals (STU:H5P), the current Beta is 0.5217 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (STU:H5P) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of €17.74 is trading 27.4% below its estimated GF Value™ of €24.42. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:H5P:

  • Beta: 0.5217
  • GF Value™: €24.42 vs. price of €17.74 (27.4% below fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the STU:H5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
84GF Score

Get the complete analysis for STU:H5P

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.74
Price
€24.42
GF Value